Of direct relevance to this review, targeted suppression of the ATF6 pathway has been demonstrated to ameliorate hypertension‐associated cardiac fibrotic remodelling and hemodynamic dysregulation, highlighting its central role in hypertensive end‐organ damage [34]. Here, ATF6 is linked to hypertensive disorder.